Schizophrenia. Schizophrenia
Conditions
Interventions
Intervention 1: Intervention group: In addition to the prescribed antipsychotic treatment that they were already taking, patients receive agomelatine tablets (Tadbir Kalaye Jam Pharmaceutical Company)
Sponsors
Ahvaz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Patients diagnosed with schizophrenia based on DSM-5 criteria Calgary Schizophrenia Depression Score (CDSS) = 18 PANSS positive symptoms subscale score is greater than 7 and less than or equal to 28. PANSS negative symptoms subscale score greater than or equal to 24 and at least 2 of the 3 main symptoms (emotional boredom, passive/indifferent social withdrawal and lack of spontaneity and fluency in conversation) have = 4 points.
Exclusion criteria
Exclusion criteria: Taking typical antipsychotic drugs, antidepressants, sodium valproate, lithium, and benzodiazepines The presence of accompanying psychiatric disorders such as schizoaffective or other psychotic disorders, bipolar disorder, anxiety disorders such as panic disorder or obsessive-compulsive disorder, post-traumatic stress disorder, eating disorder Current or past (past 6 months) diagnosis of severe personality disorders that would compromise the participant's ability to perform the study requirements. Hypersensitivity to agomelatine or any of the ingredients of the placebo
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 5-DSM. Timepoint: Before the intervention, 2 and 4 weeks after the intervention. Method of measurement: Interview.;CDSS. Timepoint: Before the intervention, 2 and 4 weeks after the intervention. Method of measurement: Interview.;PANSS. Timepoint: Before the intervention, 2 and 4 weeks after the intervention. Method of measurement: Interview. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactTahereh Amirshekari
Ahvaz University of Medical Sciences
Outcome results
None listed